Figure 4
Comparing patients treated with allogeneic and autologous HSCT (Gray test). Cumulative incidence of development of a de novo cardiovascular risk factor after treatment with HSCT. (A) Arterial hypertension. (B) Dyslipidemia. (C) Diabetes. (D) BMI greater than 25 kg/m2.
